Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2026 aims to ensure reasonable prices for biomedical products developed with federal.

The Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2026 mandates that federal agencies require reasonable pricing for biomedical products developed with federal research funding. The Secretary of Health and Human Services determines what constitutes a reasonable price, ensuring that U.S. residents do not pay more than the median price in six reference countries with large economies and high incomes. The act also allows for waivers of these pricing obligations if deemed in the public interest, provided certain conditions are met.

Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2026 aims to ensure reasonable prices for biomedical products developed with federal.

The Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2026 mandates that federal agencies require reasonable pricing for biomedical products developed with federal research funding. The Secretary of Health and Human Services determines what constitutes a reasonable price, ensuring that U.S. residents do not pay more than the median price in six reference countries with large economies and high incomes. The act also allows for waivers of these pricing obligations if deemed in the public interest, provided certain conditions are met.